DOCHEALTHPEAK PROPERTIES, INC.(DOC)Stock Analysis

AI analysis on 2,800+ stocks →
Real EstateNYSE
Institutional-grade research for retail investors
SEC EDGAR: CIK 765880DOC stock profile & AI dashboard →

13F Pro Quality Score

62.0/100

Rank #763 of 2,879 stocksTOP 50%

View Real Estate peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

66.8/100

Profitability

81.3/100

Balance Sheet

41.3/100

Earnings Quality

17.9/100

Free Cash Flow

97.1/100

Institutional Flow

16.7/100

Revenue Scale

41.1/100

Dilution Risk

74.7/100

DOC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for HEALTHPEAK PROPERTIES, INC. (DOC), a Real Estate sector company. 13F Pro's AI-powered ranking engine scores DOC at 62.0/100 on a 32-signal composite quality model, placing it at rank #763 of 2,879 stocks — the top half of the AI-ranked universe. DOC scores in the top quartile across free cash flow (97.1), profitability (81.3). Areas of concern include institutional flow (16.7) and earnings quality (17.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), HEALTHPEAK PROPERTIES, INC. reports quarterly revenue of $753.0M, net income of $193.6M, free cash flow of $260.9M. DOC trades on the NYSE exchange and files with the SEC under CIK 765880. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DOC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HEALTHPEAK PROPERTIES, INC. directly from SEC EDGAR. HEALTHPEAK PROPERTIES, INC.'s 13F Pro composite quality score has ranged between 8 and 75 since 2021, currently 62.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$753.0M

Net Income

Q1 2026

$193.6M

Free Cash Flow

Q1 2026

$260.9M

ROIC

Q1 2026

1.1%

D/E Ratio

Q1 2026

1.33

AI Insight: DOC Financial Trends

Revenue accelerated to a record $753M in Q1 2026, but total debt surged 21% from Q2 2024 to $10,423M while equity eroded from $8,757M to $7,826M.

Revenue grew from $696M in Q2 2024 to $753M in Q1 2026, the strongest quarterly reading in the dataset.

Total debt climbed from $8,603M in Q2 2024 to $10,423M in Q1 2026, a $1,820M increase over six quarters.

Equity contracted from $8,757M in Q2 2024 to $7,826M in Q1 2026, compressing the equity cushion against rising debt.

Operating cash flow fell from $318M in Q3 2024 to $261M in Q1 2026, the lowest level in the dataset.

Debt-to-equity ratio worsened from ~0.98x in Q2 2024 to ~1.33x in Q1 2026 — rising leverage warrants monitoring.

Net income swung from $194M in Q1 2026 but hit -$117M in Q3 2025 — earnings volatility signals lumpy asset gains/losses.

Operating cash flow declining while revenue rises could indicate growing non-cash revenue or working capital pressure.

AI Insight: DOC Ratio Trends

Q1 2026 operating margin surged to 26.0% — the strongest quarterly reading in the dataset — masking persistent TTM profitability drag from Q3 2025's -16.6% NPM.

Operating margin rebounded sharply from -0.5% in Q4 2024 to 26.0% in Q1 2026, the highest level across all periods shown.

ROIC recovered to 4.3% in Q1 2026 from a trough of -0.1% in Q4 2024, signaling improving capital efficiency.

Debt-to-equity has steadily risen from 0.98 in Q2 2024 to 1.33 in Q1 2026, reflecting increasing balance-sheet leverage.

TTM NPM stands at only 7.7%, depressed by Q3 2025's -16.6% net margin, which appears driven by a one-off charge.

D/E climbing from 0.98 to 1.33 over four quarters — sustained leverage expansion warrants monitoring given rising interest costs.

Q1 2026's 26.0% operating margin is a significant sequential spike; confirm whether it reflects recurring operations or asset-sale gains.

Q3 2025's -16.6% NPM suggests a material one-time item; recurrence risk or hidden impairments should be tracked.

Get alerted when DOC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HEALTHPEAK PROPERTIES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put DOC on your watchlist

Track score changes the day HEALTHPEAK PROPERTIES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is DOC a good stock to buy?

13F Pro's AI-powered analysis of HEALTHPEAK PROPERTIES, INC. (DOC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Real Estate sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DOC are available on the DOC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DOC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DOC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HEALTHPEAK PROPERTIES, INC.'s investment landscape.